Volume | 1,360,532 |
|
|||||
News | - | ||||||
Day High | 1.70 | Low High |
|||||
Day Low | 1.53 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Atossa Therapeutics Inc | ATOS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.53 | 1.53 | 1.70 | 1.66 | 1.52 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,067 | 1,360,532 | $ 1.64 | $ 2,227,265 | - | 0.62 - 2.31 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:05:21 | formt | 200 | $ 1.66 | USD |
Atossa Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
208M | 125.30M | - | 0 | -30.09M | -0.24 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Atossa Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATOS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.58 | 1.70 | 1.47 | 1.52 | 1,115,958 | 0.08 | 5.06% |
1 Month | 2.17 | 2.31 | 1.24 | 1.65 | 2,254,120 | -0.51 | -23.50% |
3 Months | 0.94 | 2.31 | 0.90 | 1.60 | 1,850,714 | 0.72 | 76.60% |
6 Months | 0.6924 | 2.31 | 0.62 | 1.45 | 1,073,877 | 0.9676 | 139.75% |
1 Year | 0.65 | 2.31 | 0.62 | 1.27 | 871,176 | 1.01 | 155.38% |
3 Years | 2.40 | 9.80 | 0.50 | 3.82 | 3,196,567 | -0.74 | -30.83% |
5 Years | 2.97 | 9.80 | 0.50 | 3.20 | 3,481,342 | -1.31 | -44.11% |
Atossa Therapeutics Description
Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. |